About Servier Symphogen
Servier Symphogen is a company based in Ballerup (Denmark) founded in 2000 was acquired by Servier in April 2020. It operates as a Professional Services. Servier Symphogen has raised $671.45 million across 15 funding rounds from investors including Takeda Pharmaceuticals, HHS and Genentech. The company has 103 employees as of December 31, 2021. Servier Symphogen offers products and services including Antibody Therapeutics. Servier Symphogen operates in a competitive market with competitors including Jazz Pharmaceuticals, C4 Therapeutics, Erasca, Revolution Medicines and MiRagen, among others.
- Headquarter Ballerup, Denmark
- Employees 103 as on 31 Dec, 2021
- Stage Minicorn
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Servier Symphogen A/S
-
Annual Revenue
$73.72 M (USD)308as on Sep 30, 2021
-
Net Profit
$13.95 M (USD)142as on Sep 30, 2021
-
EBITDA
Not available
-
Total Equity Funding
$671.45 M (USD)
in 15 rounds
-
Latest Funding Round
$58.84 M (USD), Series F
May 29, 2019
-
Investors
Takeda Pharmaceuticals
& 11 more
-
Employee Count
103
as on Dec 31, 2021
-
Acquired by
Servier
(Apr 03, 2020)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Servier Symphogen
Servier Symphogen offers a comprehensive portfolio of products and services, including Antibody Therapeutics.
Antibody therapeutics are developed for cancer treatment solutions.
People of Servier Symphogen
Unlock access to complete
Unlock access to complete
Funding Insights of Servier Symphogen
Servier Symphogen has successfully raised a total of $671.45M across 15 strategic funding rounds. The most recent funding activity was a Series F round of $58.84 million completed in May 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Servier Symphogen
Servier Symphogen has secured backing from 12 investors, including institutional and venture fund investors. Prominent investors backing the company include Takeda Pharmaceuticals, HHS and Genentech.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity and venture capital fund focused on the healthcare sector
|
Locked | Locked | Locked | |
|
Growth-stage healthcare companies are invested in by EW Healthcare Partners.
|
Locked | Locked | Locked | |
|
Private equity and venture captial firm focused on healthcare sectors
|
Locked | Locked | Locked |
Investor details for Servier Symphogen
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Servier Symphogen
Investment portfolio details for Servier Symphogen
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Servier Symphogen
Detailed financials for Servier Symphogen
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Servier Symphogen Comparisons
Peer comparison for Servier Symphogen
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Servier Symphogen
Servier Symphogen operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, C4 Therapeutics, Erasca, Revolution Medicines and MiRagen, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Cancer therapies are developed using selective pathway inhibitors.
|
|
| Locked | Locked | Locked |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
|
| Locked | Locked | Locked |
Therapeutics for cancer and rare diseases are developed.
|
Detailed competitors of Servier Symphogen
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Servier Symphogen
Complete news archive for Servier Symphogen
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Servier Symphogen
Servier Symphogen was founded in 2000.
Servier Symphogen is headquartered in Ballerup, Denmark.
Martin Olin is the current CEO of Servier Symphogen.
Servier Symphogen is a funded company, having raised a total of $671.45M across 15 funding rounds to date.
As of Dec 31, 2021, the latest employee count at Servier Symphogen is 103.
Annual revenue of Servier Symphogen is $73.72M as on Sep 30, 2021.
Servier Symphogen is recognized as the Antibody Center of Excellence within the Servier Group. The company is primarily engaged in oncology and immune oncology sectors. A highly efficient antibody discovery and research platform is utilized, supported by comprehensive early development capabilities. Unique functionalities in antibodies are delivered, offering potential for best or first-in-class treatments as combination or monotherapy. Combination therapies, central to future cancer treatments, are well-suited to the companys approach and capabilities. Scientific innovation is emphasized as the core of advancing cancer therapies.
Servier Symphogen's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.
Servier Symphogen offers Antibody Therapeutics.
Servier Symphogen has 12 investors. Key investors include Takeda Pharmaceuticals, HHS, Genentech, Servier, and Danica Pension.
The valuation of Servier Symphogen is $281.31M as of May 2019.